Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and ...

To overcome such inherent challenges, scientists are turning to more robust molecular solutions that improve cancer cell targeting and therapeutic outcomes, among the most promising of which are ...

In less than a decade, bispecific antibodies have gone from scientific curiosity to frontline cancer therapeutics. These engineered proteins, capable of binding to two or more targets simultaneously, ...

While 2025 has not been a banner year for biopharma dealmaking, antibodies that bind two or more molecular targets—so-called multispecifics—have taken center stage. The top three licensing deals and ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...